Latest news for LGX Oil & Gas (OTC:ROAOF) Stock

LGX Oil & Gas Inc is a junior oil and gas company. The company is engaged in the acquisition, exploration, development, and production of oil and gas properties. Its projects are in Southern Alberta. The company invests in all types of energy business-related assets, including petroleum and natural gas-related assets, gathering, processing, and transportation assets located in Western Canada. LGX is dedicated to delivering growth in reserves and production for its investors through land acquisition, exploration, and development of oil and natural gas resources.

LGX Oil & Gas Inc

Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) gains significant leverage in future litigation after <a href="https://www.benzinga.com/24/12/42633922/qualcomm-bags-win-in-chips-licensing-trial-against-arm-but-the-battle-is-not-over-yet">securing a critical legal win</a> against Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), according to JPMorgan analyst Samik Chatterjee.
What The Court Said: A Delaware District Court ruled that Qualcomm's acquisition of Nuvia did not violate Arm's Architecture License Agreement (ALA), securing the designs under Qualcomm's license. 
While the verdict didn't resolve all questions about Nuvia's prior actions, it eliminates fears of canceled licenses or disruptive financial repercussions.
It also dismisses major uncertainties surrounding the license agreement with Arm and allows San Diego-based Qualcomm to continue selling and innovating on Arm&#8217;s chips without interruption.
Still, Chatterjee warns of potential future litigation from Arm and hints at possible renegotiations over financial terms for ALA extensions beyond 2033. Qualcomm has the option to renew the license for an additional five years in 2028 for just $1 million annually—a move that could be pivotal for its long-term roadmap.
Read More: <a href="https://www.benzinga.com/24/12/42633922/qualcomm-bags-win-in-chips-licensing-trial-against-arm-but-the-battle-is-not-over-yet">Qualcomm Bags Win In Chips Licensing Trial Against Arm, But The Battle Is Not Over Yet</a>
Beyond The Courtroom: Trial disclosures revealed Qualcomm's ambitious plans post-Nuvia acquisition, including four groundbreaking CPU design efforts:
<ul>
<li>Hamoa – Aimed at PCs and laptops.</li>
<li>Pakala – Targeting the smartphone market.</li>
<li>Nordschleife – Designed for automotive applications.</li>
<li>Pegasus – Focused on future computing and mobile innovations.</li>
</ul>
<ol></ol>
While these efforts showcase Qualcomm's R&amp;D prowess, Arm's potential plans to develop its own processors — possibly for Samsung — add an intriguing layer of competition.
<h2 class="wp-block-heading">Bearish Signals Dominate</h2>
Despite the legal victory, Qualcomm's stock isn't getting much love from the technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23052409/Screenshot-2024-12-23-at-3.53.42-PM.png" alt="" class="wp-image-703803" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23052409/Screenshot-2024-12-23-at-3.53.42-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23052409/Screenshot-2024-12-23-at-3.53.42-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Trading at $152.89, QCOM stock lags below its eight-day, 20-day, 50-day, and 200-day simple moving averages—all flashing bearish signals. 
The Moving Average Convergence Divergence (MACD) at a negative 2.73 and a Relative Strength Index (RSI) of 39.6 suggest QCOM stock is nearing oversold territory, but bears remain in control.
Chatterjee maintains an &#8216;Overweight&#8217; rating for Qualcomm stock, citing its ability to navigate legal challenges and drive innovation. 
However, the road ahead could see bumps if Arm chooses to escalate disputes or Qualcomm faces challenges in renegotiating license terms.
For Qualcomm investors, the court ruling removes a major overhang, clearing the way for further innovation in Arm-based chips. 
Yet, with bearish technicals and lingering uncertainties about Arm's next moves, the stock remains a high-stakes play.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a></li>
</ul>
Image: Shutterstock

Analyst Color

Government

Long Ideas

Regulations

Technicals

Legal

Analyst Ratings

Tech

Trading Ideas

QCOM

Qualcomm Scores Big In Arm Lawsuit: Will Bearish Trends Back Down?

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
WVE-007 is Wave's first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery
Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025
CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the submission of its first clinical trial application (CTA) for WVE-007 in obesity. WVE-007 is an investigational GalNAc-conjugated small interfering RNA (siRNA) designed to silence Inhibin&nbsp;βE (INHBE) gene expression, which would induce fat burning (lipolysis) to decrease body weight without impacting muscle mass. Wave expects CTA approval and initiation of the first-in-human study of WVE-007 in the first quarter of 2025.

Biotech

News

General

Wave Life Sciences Announces Submission Of First Clinical Trial Application For WVE-007 In Obesity

Keybanc analyst Tim Rezvan maintains BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) with a Overweight and raises the price target from $23 to $25.

Price Target

Keybanc Maintains Overweight on BKV, Raises Price Target to $25

WIIM

Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.

As of Dec. 23, 2024, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Profire Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIE#NASDAQ">PFIE</a>)</h3>
<ul>
<li>On Nov. 6, Profire Energy posted in-line quarterly earnings. The company's stock surged around 79% over the past six months and has a <a href="https://www.benzinga.com/quote/PFIE">52-week high of $2.55</a>.</li>
<li>RSI Value: 70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PFIE Price Action: Shares of Profire Energy closed at $2.54 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Adams Resources &amp; Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AE#NYSE">AE</a>)</h3>
<ul>
<li>On Nov. 12, Adams Resources &amp; Energy posted better-than-expected quarterly sales. &#8220;We are encouraged by the increase in Adjusted EBITDA from crude oil marketing operations, as higher oil prices compared to the prior-year quarter more than offset the lower volumes related to our exit of the Red River operations in the fourth quarter of 2023,&#8221; said Kevin Roycraft, President and CEO of the Company. The company's stock gained around 52% over the past six months and <a href="https://www.benzinga.com/quote/AE">has a 52-week high</a> of $37.90.</li>
<li>RSI Value: 76</li>
<li>AE Price Action: Shares of Adams Resources &amp; Energy closed at $37.30 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

PFIE

Top 2 Energy Stocks That May Dip This Quarter

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/20/final-trades-freeport-mcmoran-columbia-banking-pg-and-target.html">Halftime Report Final Trades</a>,&#8221; Sarat Sethi of DCLA said he likes Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>).
On Oct. 22, Freeport-McMoRan reported third-quarter FY24 results. Revenue stood at $6.79 billion, beating the consensus of $6.47 billion. Copper sales totaled 1.0 billion pounds, down 7% Y/Y and 2% above the July 2024 estimate, due to the timing of shipments and lower ore grades and operating rates in <a href="https://www.benzinga.com/quote/FCX/earnings">North America</a>.
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) has a 5.3% dividend yield.
On Dec. 17, UBS analyst Nicholas Holowko assumed Columbia Banking System with a Neutral rating and announced a price target of $32.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson of Capital Wealth Planning named The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), which has a 2.5% dividend yield.
Procter &amp; Gamble will webcast a discussion of its second quarter earnings results on Jan. 22, 2025. Analysts expect the company to report quarterly earnings at $1.88 per share on revenue of $21.74 billion.
Stephanie Link of Hightower Advisors named Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) as her final trade.
On Dec. 20, Stifel analyst Mark Astrachan maintained Target with a Hold and raised the price target from $137 to $145.
Price Action:
<ul>
<li>Freeport-McMoRan shares gained by 1.6% to close at $38.86 on Friday.</li>
<li>Columbia Banking shares gained 3% to close at $27.19 during Friday's session.</li>
<li>Procter &amp; Gamble shares fell by 0.7% to settle at $168.06 on Friday.</li>
<li>Target gained by 0.8% to settle at $131.48 during Friday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Image generated using artificial intelligence via Midjourney

Media

COLB

Procter & Gamble, Freeport-McMoRan, Columbia Banking And A Major Retailer On CNBC's 'Final Trades'

<ul>
<li>In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) &amp; gene fusion assays</li>
<li>OGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotyping</li>
<li>When OGM results and next-generation sequencing (NGS) results were combined, diagnostic and pathogenic structural variants (SVs), copy number variants (CNVs), and/or single nucleotide variants (SNVs) were found in ~98% of cases, a substantially greater rate than when karyotyping, FISH and NGS are used &nbsp;</li>
</ul>
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) today announced a publication in&nbsp;Modern Pathology by a group of researchers at the&nbsp;Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors.

BNGO

Bionano Announces Publication From Johns Hopkins School Of Medicine Showing That OGM Outperformed Multiple Cytogenetic Assays In A Study Of Bone And Soft Tissue Tumor Analysis

Ormat Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>), a leading geothermal and renewable energy company, today announced it has successfully secured 1,678 acres in Utah's Bureau of Land Management (BLM) Auction. These lease acquisitions will significantly support Ormat's ongoing operations and development projects in the state, further strengthening the company's commitment to advancing renewable energy solutions and meeting Utah's increasing demand for sustainable energy.
The newly leased acres should allow Ormat to develop two new power plants near our Cove Fort facility in Utah. Exploration work on the first plant (Cove Fort 2) is expected to begin in 2025 and, pending resource availability, we expect the project to achieve a Commercial Operation Date in 2027. The second plant (Cove Fort North) will be developed at a later stage.

Ormat Technologies Secured 1,678 Acres In Utah's Bureau Of Land Management Auction To Support Ormat's Ongoing Operations And Development Projects In The State, Further Strengthening The Co's Commitment To Advancing Renewable Energy Solutions And Meeting Utah's Increasing Demand For Sustainable Energy

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger
The Financing includes both new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed
The transaction is expected to close in mid-2025
BOSTON and SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>, "Ikena, "))) and Inmagene Biopharmaceuticals ("Inmagene") announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into subscription agreements for a $75 million private placement (the "Financing") with a syndicate that includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will focus on the development of IMG-007, a monoclonal antibody (mAb) targeting OX40, for the treatment of atopic dermatitis. The combined company plans to operate under the name "ImageneBio, Inc." ("ImageneBio") and trade on NASDAQ under the ticker "IMA".

IKNA

Ikena And Inmagene Enter Merger Agreement; $175M To Support IMG-007 Development, Includes $75M Private Placement; Combined Company ImageneBio To Target Atopic Dermatitis; Expected Close Mid-2025 And Trade On Nasdaq Under The Ticker "IMA"

DESP

Despegar shares are trading higher. The company announced it will be acquired by Prosus in $1.7 Billion deal.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Monday.
Shares of Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell sharply in today's pre-market trading after a US jury reportedly found Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) did not breach Nuvia&#8217;s license agreement <a href="https://www.benzinga.com/quote/ARM">with the company</a>.
Arm Holdings shares fell 2.3% to $129.14 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) shares dipped 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares declined 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) declined 8.5% to $5.41 in pre-market trading.</li>
<li>Dnow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNOW#NYSE">DNOW</a>) fell 7.7% to $11.90 in pre-market trading.</li>
<li>DiamondRock Hospitality Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) fell 4.3% to $8.92 in pre-market trading.</li>
<li>NI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NODK#NASDAQ">NODK</a>) fell 3.8% to $14.73 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Movers

ATXS

DNOW

NODK

SIGA

Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Immediately prior to the closing (the "Effective Date"), all Foremost shareholders are expected to receive two shares of Rio Grande for every one share of Foremost they hold
VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Foremost Clean Energy Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/FMST#NASDAQ">FMST</a>) (CSE:<a href="https://www.benzinga.com/stock/FAT#CSE">FAT</a>) ("Foremost" or the "Company"), an emerging North American uranium and lithium exploration company, is pleased to announce that shareholders of Foremost ("Shareholders") have approved the previously announced plan of arrangement (the "Arrangement") under which the Company will spin-out its gold and silver properties located in Sierra County, New Mexico, United States (collectively, the "Winston Property") to Shareholders through Rio Grande Resources Ltd. ("Rio Grande"), a wholly-owned subsidiary of the Company.

FMST

Foremost Clean Energy Announces Approval Of The Winston Gold And Silver Spin-Out

Nordstrom Shareholders to Receive $24.25 Per Share in Cash
Transaction Represents a Premium of Approximately 42% Since March 18, 2024
Board Also Intends to Pay Special Dividend of Up to $0.25 Per Share in Cash Contingent on Closing
SEATTLE, Dec. 23, 2024 /PRNewswire/ -- Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) today announced it has signed a definitive agreement under which Erik, Pete, Jamie Nordstrom and other members of the Nordstrom family (collectively, the "Nordstrom Family") and El Puerto de Liverpool, S.A.B. de C.V. ("Liverpool") (BMV:<a class="ticker" href="https://www.benzinga.com/stock/LIVEPOL#BMV">LIVEPOL</a>) will acquire all of the outstanding common shares of Nordstrom not already beneficially owned by the Nordstrom Family and Liverpool in an all-cash transaction valued at approximately $6.25 billion on an enterprise basis. Following the close of the transaction, the Nordstrom Family will have a majority ownership stake in the Company.
Under the terms of the agreement, Nordstrom common shareholders will receive $24.25 in cash for each share of Nordstrom common stock they hold. The merger consideration represents a premium of approximately 42% to the Company's unaffected closing common stock price on March 18, 2024, the last trading day prior to media speculation regarding a potential transaction. In addition, the Board intends to authorize a special dividend of up to $0.25 per share (based on Nordstrom's cash on hand) immediately prior to and contingent on the close of the transaction. Upon completion of the transaction, Nordstrom will become a private company.&nbsp;

BMV:LIVEPOL

Nordstrom To Be Acquired By Nordstrom Family And Liverpool For $24.25 Per Share In $6.25B Deal; Includes 42% Premium And Special $0.25 Dividend, With Plans To Go Private

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases.
Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Van Hyfte and Ingrid Brands collectively acquired a total of 763,120 shares of IPA on the open market for an aggregate amount of USD $306,000.

Insider Trades

ImmunoPrecise Antibodies CEO Jennifer Bath And BioStrand Co-Founders Dirk Van Hyfte And Ingrid Brands Collectively Acquired A Total Of 763,120 Shares Of IPA On The Open Market For An Aggregate Amount Of $306,000

Loop Capital analyst Anthony Chukumba maintains Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Buy and raises the price target from $120 to $130.

OLLI

Loop Capital Maintains Buy on Ollie's Bargain Outlet, Raises Price Target to $130

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com&amp;esheet=54170302&amp;newsitemid=20241223192260&amp;lan=en-US&amp;anchor=Hyliion+Holdings+Corp.&amp;index=1&amp;md5=58a8e4699371f2ab58ac0b42012d441f">Hyliion Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>), a developer of sustainable electricity-producing technology, today announced it has been awarded a $6 million grant from the U.S. Department of Energy's (DOE) Methane Emissions Reduction Program. For this project, representing a total of $8.4 million in federal and non-federal funding, Hyliion will install up to 2 megawatts of KARNO&#x2122; generators in collaboration with oil and gas partners.
The project will demonstrate the KARNO generator's unique ability to operate on well-head gas to produce sustainable, near-zero emissions electricity. In 2023, Hyliion <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com%2Fnews%2Fhyliions-karno-technology-successfully-tests-on-unprocessed-permian-basin-gas%2F&amp;esheet=54170302&amp;newsitemid=20241223192260&amp;lan=en-US&amp;anchor=successfully+tested&amp;index=2&amp;md5=e2e75dc850640b8c7be7afb60099e6d8">successfully tested</a> gas from the Permian Basin, highlighting the generator's fuel-agnostic design and its capability to utilize unprocessed gas. This distinctive capability positions the KARNO generator as a groundbreaking solution for reducing flaring and methane emissions while delivering efficient, scalable power.

Contracts

HYLN

Hyliion Awarded $6M Federal Grant To Advance Methane Emission Reductions In The Oil And Gas Industry

<ul>
<li>Brenmiller is replacing Tempo's fossil fuel boilers with a 32 MWh bGen&#x2122; thermal energy storage system to deliver sustainable process heat that is expected to mitigate 6,200 tons of carbon emissions annually</li>
<li>Tempo, partially owned by Heineken International B.V., is one of Israel's largest producers and distributors of beverages for brands including Heineken and Pepsi</li>
<li>Completion of the Tempo project as planned is expected to accelerate and support the conversion of Brenmiller's current substantial $440 million dollar commercial pipeline into projects with revenues</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbren-energy.com%2F&amp;esheet=54170268&amp;newsitemid=20241223885043&amp;lan=en-US&amp;anchor=Brenmiller+Energy+Ltd.&amp;index=1&amp;md5=a98275ef42bf19bf89bc8aef00265228">Brenmiller Energy Ltd.</a> ("Brenmiller", "Brenmiller Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>), a leading global technology provider of thermal energy storage ("TES") solutions to industrial and utility customers, today announced that it has achieved a major contractual milestone in its groundbreaking TES project for Tempo Beverages Ltd. ("Tempo") and a critical financial benchmark representing 40% of Tempo's financial commitment to the project.

BNRG

Brenmiller Energy Achieves Significant Project Milestone, On-Track To Save Tempo Beverages $7.5M In Energy Costs Using Thermal Energy Storage,  Representing 40% Of Tempo's Financial Commitment To The Project

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares are trading higher premarket on Monday. On Saturday, the company successfully completed its 16th launch of the year, deploying a satellite for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42635442/rocket-lab-successfully-deploys-satellite-for-synspective-caps-off-year-with-60-increase-in-launch" rel="noreferrer noopener">Japanese Earth-observation operator</a> Synspective.
This marks the sixth of 16 planned Electron launches for Synspective. Rocket Lab has been Synspective&#8217;s exclusive launch provider since their first mission together in December 2020.
The &#8220;Owl The Way Up&#8221; mission launched from Rocket Lab&#8217;s Launch Complex 1 in Mahia, New Zealand, on December 22 at 03:17 NZT, successfully deploying a single StriX satellite into orbit via the Electron launch vehicle.
Rocket Lab founder and CEO Sir Peter Beck stated, &#8220;We look forward to continuing to increase our launch cadence in the new year as we strengthen Electron&#8217;s position as the leading small rocket globally and also enter the medium launch market with Neutron&#8217;s debut.&#8221;
Earlier this month, the company had announced &#8220;Owl The Way Up&#8221; mission, <a target="_blank" href="https://www.benzinga.com/24/12/42371072/whats-going-on-with-rocket-lab-stock-today" rel="noreferrer noopener">which is the final launch of the year</a>.
Notably, 2024 has been a remarkable year for Rocket Lab, with 16 launches so far, surpassing its previous annual record of 10 missions in 2023.
The company maintained a perfect 100% mission success rate for all 2024 launches. The company has scheduled the next Electron launch for Q1 2025.
Last week, Rocket Lab successfully delivered its second Pioneer spacecraft to Vandenberg Space Force Base and completed production <a target="_blank" href="https://www.benzinga.com/general/space/24/12/42539487/whats-going-on-with-rocket-lab-stock-tuesday-2" rel="noreferrer noopener">and testing of a third spacecraft for Varda</a>.
Investors can gain exposure to the stock via&nbsp;Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and&nbsp;SPDR S&amp;P Kensho Final Frontiers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROKT#NYSE">ROKT</a>).
Price Action: RKLB shares are up 1.61% at $25.27 premarket at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42470053/josh-brown-unveils-the-degen-dow-a-basket-of-30-retail-darlings-spanning-all-major-degen-food-groups" target="_blank" rel="noreferrer noopener">Josh Brown Unveils The &#8216;Degen Dow,&#8217; A Basket Of 30 Retail Darlings Spanning All &#8216;Major Degen Food Groups&#8217;</a></li>
</ul>

Equities

Large Cap

RKLB

ROKT

Rocket Lab Ends 2024 With 16th Launch, Stock Gains

Loop Capital analyst Alan Gould maintains News (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>) with a Buy and lowers the price target from $44 to $41.

NWSA

Loop Capital Maintains Buy on News, Lowers Price Target to $41

Xerox Holdings shares are trading higher after the company announced it agreed to acquire Lexmark International from Ninestar Corporation, PAG Asia Capital and Shanghai Shouda Investment Centre.

Comments

LGX Oil & Gas

News

Latest news for LGX Oil & Gas (OTC:ROAOF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga